HeartBeam, Inc. Form 8-K Summary
Business Context and Reporting Period
HeartBeam, Inc. filed this Current Report on February 2, 2023, reporting that it entered into a Sales Agreement with A.G.P./Alliance Global Partners on February 1, 2023. The filing concerns a potential equity financing and does not include quarterly or annual operating results.
Financing and Key Terms
- The company may offer and sell up to approximately $13.0 million of common stock through an at-the-market offering under its Form S-3 registration statement.
- Sales may occur from time to time at the company’s discretion, through or to A.G.P., subject to the agreement’s terms and applicable securities laws and Nasdaq rules.
- A.G.P. will receive a commission equal to 3.0% of aggregate gross proceeds from each sale, in addition to reimbursement of certain expenses.
- Net proceeds are expected to be used for working capital and other general corporate purposes, or as otherwise specified in a future prospectus supplement.
- The filing does not state that any shares had been sold or that any proceeds had been received as of the filing date.
Material Changes, Outlook, and Risks
The material change reported is the execution of the potential equity financing facility. The company stated that it cannot assure that it will issue any shares under the Sales Agreement. If shares are issued, the financing could increase cash resources but dilute existing stockholders. The filing provides no revenue, profit, cash flow, margin, debt, liquidity balance, or operating guidance information.
Important Facts to Verify
- Actual shares sold, average sale price, gross proceeds, commissions, and net proceeds under the Sales Agreement.
- Remaining availability under the approximately $13.0 million offering.
- The company’s cash balance, cash burn, and liquidity outlook in its next periodic filing.
- Any subsequent prospectus supplements describing offering terms or intended use of proceeds.
- Potential dilution to existing holders of common stock and warrants.